3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Neoplasms
1
Interventions
pembrolizumab
46
Paclitaxel
46
Gemcitabine
41
Carboplatin
37
Docetaxel
35
Bevacizumab
27
Cisplatin
25
Irinotecan
22
Nivolumab
20
Fluorouracil
20
Erlotinib Hydrochloride
18
Pemetrexed
17
Capecitabine
17
Sorafenib
16
Magnetic Resonance Spectroscopy
16
Cetuximab
16
Afatinib
16
Leucovorin
15
regorafenib
14
olaparib
13
Specimen Handling
13
Oxaliplatin
13
trametinib
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
eribulin
10
atezolizumab
10
epothilone B
9
Radiotherapy
9
Midazolam
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rosiglitazone
×
Tumor-Agnostic
×
Clear all
NCT01287598
2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1
Completed
41 enrolled